CCBF welcomes Dr. Sujit Sheth as the new Chief of the Division of Pediatric Hematology and Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Sheth joins the Division after 19 years at NewYork-Presbyterian Morgan Stanley Children's Hospital at Columbia University Medical Center. Prior to his career at Columbia, Dr. Sheth received his medical degree and completed his resident specialty training in Pediatrics at the University of Bombay. He then came to the U.S. to pursue a Post-Doctoral Fellowship in Pediatric Hematology Oncology at the Children's Hospital at Columbia University Medical Center.
An award-winning physician and clinical researcher, Dr. Sheth has previously been voted both teacher and attending of the year at Columbia. He completed work on his NIH grant "Mentored Patient-Oriented Hematology Research Training," and has been a co-investigator in several NIH studies. Dr. Sheth's clinical interests include thalassemia, anemia, sickle cell anemia and all things related to iron. He is currently working on two research projects that explore different aspects of iron metabolism related to blood transfusions.
Dr. Sheth sees a bright future for the Division and has already initiated changes that will make it an even more prominent clinical, research and teaching center. His first project involves revamping the clinical operation of the Division to enhance access through efficiency, which will allow more patients to receive treatments while experiencing shorter wait times. He plans to bring newer technology into the operation, which will improve the quality of care and facilitate patient oriented research. Dr. Sheth also looks forward to creating a new and fully renovated day hospital center, which will provide a more child and family friendly environment that will make patients and their families feel welcome. Additionally, Dr. Sheth hopes to develop stronger ties with neighboring medical institutions and encourage collaborations among scientists. By collaborating on research initiatives, CCBF investigators and co-investigators from other institutions will be able to accelerate their research and bring new therapies to patients more quickly.